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Oral disintegrating tablets (ODTs) have advantages of solid dosage forms such as
good stability, accurate dosing, small packaging size, and easy handling, as well as those
of liquid formulations such as easy administration and minimal risk of suffocation.
Therefore, they are beneficial for children, elderly and schizophrenic patients who have
difficulty in swallowing conventional solid dosage forms (1). The success of ODT de-
pends on patient acceptance, palatability and the challenging aspect in the formulation
of orally disintegrating tablets is to mask the bitterness of active pharmaceutical ingredi-
ents, since most drugs have bitter taste. The distasteful sensation of a drug can be mas-
ked either by the addition of flavors, sweeteners and effervescent agents or by reducing
direct contact with the patient’s taste buds through coating or granulation (2, 3). Flavor
is often overpowered by the taste of the medicine and the use of effervescent agents is
not always convenient. Moreover, coating and granulation of the active ingredient may
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often rupture during compression and chewing of the tablet, as well as contribute to a
gritty feel.
Drug binding to ion exchange resin is a simple and efficient technique of masking
drug bitterness. Active ingredients, if ionized, can be bound with fixed ions of ion-ex-
change resins (4–6). The advantages of utilizing ion-exchange resins include the simple
preparation method and no uncontrolled burst effect in the drug resinate even in case of
high drug loading. The only limiting factor for drug loading is the limited exchanging
capacity of the resin. Particle size of the resin has been reported to have a pronounced
effect on the rate and extent of drug loading (7). When active ingredient/resin comple-
xes are administered orally, the active ingredient can be released by the ion-exchange re-
action with ions present in the GI tract.
Dextromethorphan hydrobromide is an antitussive agent, used to relieve cough.
The commercial formulations available for DXM are syrups, lozenges and spray forms
but its availability as solid dosage forms is limited. Since liquid dosage forms are bulky
and stability is a key issue, we decided to develop taste masked ODTs of DXM for im-
mediate relief of cough with improved patient compliance. This could be achieved by
selecting appropriate pharmaceutical excipients in correct proportion, in combination
with optimal manufacturing techniques and compression parameters.
EXPERIMENTAL
Materials
Ion-exchange resin (Amberlite® IRP69, sodium polystyrene sulfonate (150–125,
106–75 and 63–45 mm) was donated by Rohm and Haas, USA. Dextromethorphan hydro-
bromide monohydrate (DXM) was obtained from Dr. Reddy’s Laboratories Ltd, India.
The diluents used were spray-dried mannitol (Pearlitol® SD 200, Roquette Frères,
France) and microcrystalline cellulose (Avicel PH 101, FMC International, Ireland). The
superdisintegrants used were Crospovidone (CP) (Polyplasdone XL-10, ISP Technolo-
gies, Inc, USA), sodium starch glycolate NF (SSG) (Primojel, DMV International, USA)
and Amberlite IRP88 (potassium salt of methacrylic acid polymer with divinyl benzene,
Rohm and Haas, USA). The glidants used were colloidal silicone dioxide NF (Aerosil®,
Evonik Industries Degussa, Belgium) and sodium starch fumarate (JRS Pharma, Spain).
The flavor used was tutti frutti flavor (Firmenich, India). All other chemicals and sol-
vents used were of analytical grade.
Methods
Preparation of drug resinate. – Drug resinates were prepared by a single batch process.
Purified resin (3.0 g) was placed in 200 mL of 1.5 % (m/V) of DXM aqueous solution.
The mixture was stirred for 24 h on a magnetic stirrer at ambient temperature and inter-
mittently the supernatant was removed to find out the amount of drug loaded in the
resin spectrophotometrically at 278 nm (UV-2450/2550, Shimadzu, Japan). The resinate
was retrieved by filtration and washed repeatedly with deionized water until the free
drug was removed. The resinates were dried for 2 h at 60 °C and stored in a tightly
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closed vial. The drug content in the final filtrate was analyzed at 278 nm. The amount of
drug in the resinate was obtained by subtracting the amount of drug in final filtrate from
the initial amount. Since the particle size of resin influences the extent of drug loading,
we have tested different ranges of Amberlite® IRP69 particle size.
In vitro dissolution. – Dissolution study on resinates of different particle size
(150–125, 106–75 and 63–45 mm) equivalent to 30 mg of DXM was carried out in 900 mL
of simulated gastric fluid (SGF), without enzymes, using USP dissolution apparatus (8),
type II (rotating paddle), maintained at 37 ± 0.5 °C and mixed at 50 rpm. Based on the
dissolution data, we have selected Amberlite IRP69 of particle size 63–45 mm for further
studies.
Differential scanning calorimetry (DSC). – The molecular state of the drug in the resinate
was evaluated by performing DSC analyses of pure drug, resin, physical mixture and
resinate. DSC curves of the samples were obtained with a differential scanning calorime-
ter (DSC 6, Perkin Elmer, USA). Each sample was placed in an aluminum pan and then
crimped with an aluminum cover. Heating and cooling rates were 10 and 250 °C min–1,
respectively. All measurements were performed over 40–250 °C under a nitrogen purge
at 50 mL min–1.
X-ray powder diffraction. – The XRPD patterns of pure drug, resin, physical mixture
and resinate were obtained using an X-ray diffractometer (X’ Pert PRO PANalytical, USA).
The measuring conditions were as follows: CuKa radiation, nickel filtered, graphite mo-
nochromator, 45 kV voltage and 40 mA current with X’celerator detector. All samples
were run at 1° (2q) min–1 from 3 to 45 ° (2q).
FTIR spectroscopy. – Chemical interaction between the drug and resin was studied
by FTIR spectroscopy. The IR spectra of the samples were obtained using a Fourier
transform infrared spectrometer (Perkin Elmer, USA). Measurements were carried out
according to the KBr disk method, the scanning range was 4000 to 450 cm–1.
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Table I. Composition of DXM oral disintegrating tablets
Ingredient
Disintegrant concentration CP/SSG/ IRP88 (%, m/m)
3 5 10
Drug-resinate (32.5 %) (mg) 65 65 65
Pearlitol® SD 200 (mg) 85 81 71
Avicel pH 101 (20 %) (mg) 40 40 40
Superdisintegrants (mg) 6 10 20
Aspartame (0.5 %) (mg) 1 1 1
Aerosol® (1 %) (mg) 2 2 2
Sodium stearyl fumarate (0.5 %) (mg) 1 1 1
Total (mg) 200 200 200
CP, SSG and IRP88 indicate Crospovidone, sodium starch glycolate and ion exchange resin, respectively.
Formulation of DXM oral disintegrating tablets. – In our preliminary studies, ODTs were
prepared using superdisintegrants like Crospovidone (CP), sodium starch glycolate (SSG)
and amberlite IRP88 at various concentrations (3, 5 and 10 % m/m, respectively). The
composition of ODTs prepared with different concentrations of superdisintegrants is shown
in Table I. Based on the disintegration time, the type and concentration of superdisin-
tegrant was selected and different batches of ODTs (A1, A2 and A3) containing diluents
like Avicel PH 101 and Pearlitol SD 200, either alone or in combination, were prepared
as outlined in Table II. All formulation components were accurately weighed, passed
through a 0.4-mm sieve (except lubricant) and mixed in a polyethylene bag for 15 min.
The blend was lubricated with sodium stearyl fumarate and Aerosil® (each passed
through 0.25-mm mesh) for another 5 min and directly compressed into tablets using an
8-station rotary tablet compression machine (Kambert, India). Round biconvex tablets of
200 mg in mass and 8 mm in diameter were prepared. Conventional tablets were also
prepared with the same formula (A1) using DXM instead of drug-resinate.
Evaluation of DXM oral disintegrating tablets
Mass variation, thickness and assay. – Mass variation was carried out using a digital
balance (Shimadzu) and thickness was measured with a digital screw gauge micrometer
(Digimatic micrometer Series 293, Mitutoyo, Japan). Accurately weighed amount of
powder equivalent to a single dose of DXM was taken, in triplicate, and assayed for the
drug content.
Hardness, friability and in vitro disintegration time. – Hardness, friability and in vitro
disintegration time (DT) of ODTs was determined as per the procedure described for un-
coated tablets in USP (8).
Wetting time and water absorption ratio. – The wetting time (WT) and water absorp-
tion ratio (R) were determined by using the procedures described in literature (9).
Taste evaluation and in vivo disintegration time. – The study was conducted after prior
approval from the Institutional Ethical Committee, St Peter’s Institute of Pharmaceutical
Sciences, Warangal, India. After informed consent from six human volunteers, taste eva-
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Table II. Composition of DXM oral disintegrating tablets containing different diluents
Ingredient A1 A2 A3
Drug-resinate (32.5 %) (mg) 65 65 65
Pearlitol® SD 200 (mg) – 111 77
Avicel pH 101 (mg) 111 – 34
Superdisintegrants (10 %) (mg) 20 20 20
Aspartame (0.5 %) (mg) 1 1 1
Aerosil® (1 %) (mg) 2 2 2
Sodium stearyl fumarate (0.5 %) (mg) 1 1 1
Total (mg) 200 200 200
luation was done by the time intensity method (10). Resinates equivalent to 30 mg of
DXM and ODT formulations, with and without flavor, were held in the mouth of six vol-
unteers for 30 seconds. Bitterness was recorded immediately according to the bitterness
intensity scale from 0 to 3 where 0, 0.5, 1, 2, and 3 indicate no, threshold, slight, moder-
ate and strong bitterness, respectively. The readings were taken immediately and at sev-
eral intervals over a period of 10 min.
Oral DT of the optimized ODT formulation (determined based on its in vitro DT and
drug release) was assessed on six healthy male human volunteers according to the pro-
cedure described by Abdelbary et al. (11). The subjects were informed of the purpose and
protocol of the study. As per the protocol, all volunteers were asked to rinse their mouth
with distilled water prior to the test. Tablets were placed on the tongue and a stopwatch
was started immediately. Volunteers were allowed to move the tablet against the upper
palate of the mouth with their tongue and cause a gentle tumbling action on the tablet
without chewing it. Time taken for the volunteer to feel that the last noticeable granule
had disintegrated in the oral cavity was considered the in vivo DT. Swallowing of saliva
was prohibited during the test, and the mouth was rinsed after each measurement. This
experiment was conducted on all six subjects and the mean ± SD were calculated for
each.
In vitro release. – Release studies of ODTs were performed according to the USP (8)
type-II dissolution apparatus (Model-TDL 08L, Electrolab, India), equipped with an auto
sampler and fraction collector. Paddle speed was maintained at 50 rpm and 900 mL of
simulated gastric fluid without enzymes was used as the dissolution medium. Samples
(5 mL) were collected at predetermined time intervals and replaced with an equal volu-
me of fresh medium to maintain sink conditions. The samples were filtered through a
0.45-mm membrane filter (Millipore, USA) and analyzed spectrophotometrically at
278 nm. Conventional tablets of DXM containing the same formula as A1 batch (DXM
instead of drug-resinate) were prepared by direct compression to compare the dissolu-
tion behavior of ODT.
Cumulative percent drug release was plotted as a function of time. Dissolution effi-
ciency (DE) was calculated from the area under the dissolution curve at time t (mea-
sured using the trapezoidal rule) and expressed as a percentage of the area of the rectan-
gle described by 100 % dissolution over the same time (12).
RESULTS AND DISCUSSION
Initially, ODTs containing superdisintegrants in concentrations of 3, 5, and 10 %
(m/m) were tested for disintegration time. The tablets showed disintegration time of
8–10 s, 13–17 s and 13–20 s with Crospovidone, sodium starch glycolate and Amberlite
IRP88, respectively (Table III). Among the superdisintegrants tested, CP at a concentra-
tion of 10 % m/m showed lower disintegration time. Since lower disintegration time is
required for an ODT, we have selected CP at a concentration of 10 % m/m, for formula-
tions of ODTs.
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Drug loading and in vitro dissolution from different particle size resinates
Drug loading was 85 % with the resin particle size 63–45 mm and this was reduced
to 75 and 50 % with an increase in the particle size of resin to 106–75 and 150–125 mm, re-
spectively (Fig. 1). A linear relation of drug loading to resin particle size was established.
As the particle size decreased, the drug loading increased significantly (7). Similar obser-
vations were made in our study as well. Fine particles have a larger surface area than
coarse particles and less internal volume for ions to diffuse, so less time is required to es-
tablish equilibrium. Similarly, desorption of bound drug from the complex is faster in fine
particles.
Particle size of resinate had an impact on the dissolution rate, as the sustained re-
lease was more evident from larger particles (13). From the dissolution profiles along
with cross-linking, particle size was reported to be an important factor in controlling the
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Fig. 1. Effect of particle size of ion-
-exchange resin on drug loading
(mean ± SD, n = 3).
Table III. Effect of superdisintegrants on in vitro DT of DXM oral disintegrating tablets














DT – dissolution time
release of the drug from ion exchange resin (14). The reduced dissolution behavior of
DXM from resinate with larger particle size might be due to the hurdles in drug move-
ment through the polymeric network requiring more time for deeply penetrated drug
molecules to elute. The dissolution of DXM was much higher from resinate with particle
sizes 63–45 and 106–75 mm compared to 150–125 mm particle size resinate (Fig. 2). Since
particle size is an important parameter for improved dissolution characteristics, we have
selected the resinate with smaller particle size of 63–45 mm.
Molecular interactions of drug and resin
Molecular interactions between drug and resin were studied using differential scan-
ning calorimetry, X-ray powder diffraction and Fourier transform infrared spectroscopy.
Fig. 3 represents the DSC curves of DXM, Amberlite® IRP69, physical mixture and
resinate. A sharp endothermic peak was observed at 123.07 °C for pure drug, indicating
the melting point of DXM. The endothermic peak of pure drug was also shown in case
of the physical mixture at 120.1 °C. On the other hand, no intense peak over the range of
40–250 °C was found in the DSC thermogram of resinate, which clearly indicates that
the drug was not in its native form in the resinate. This finding could be considered in-
dicative of drug amorphization as a consequence of interaction between the components
(15), which was further confirmed by XRPD analysis.
The XRPD of the pure drug contained a number of sharp peaks, while the resin
showed diffused peaks. The XRPD of the physical mixture exhibited simply the sum of
characteristic peaks of the pure drug and diffused peaks of the resin, whereas the char-
acteristic peaks of the pure drug were absent in the resinate (Fig. 4). On the basis of
diffractograms, it can be said that pure crystalline drug was found to convert into amor-
phous form with monomolecular dispersion in the resin (16). This was supported by the
absence of sharp peaks of the drug in the resinate. These results coincide with those ob-
tained by Akkaramongkolporn and co-workers (17), who studied the change in molecu-
lar properties of propranolol upon binding with an ion exchanger.
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Fig. 2. Dissolution profiles of
different particle size resina-
tes in simulated gastric fluid
(pH 1.2) (mean ± SD, n = 3).
From Fig. 5, it is evident that the FTIR spectra of the physical mixture exhibited su-
perimposition of the drug and resin spectra. This indicates that there was no appreciable
interaction between the drug and resin in the physical mixture, which is in accord with
the results from DSC and XRPD. The spectra of the resinate in the 2000–400 cm–1 region
had a similar result, demonstrating the presence of the drug in the complex. However,
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Fig. 3. DSC curves of dex-
tromethorphan, Amberlite
IRP69, physical mixture and
drug resinate.





















Fig. 4. XRPD patterns
of dextromethorphan,
Amberlite IRP69, phy-
sical mixture and drug
resinate.
around 4000–2000 cm–1 the spectrum was obviously different from the combination of
each component. Drug spectrum shows that prominent absorption bands at 2167.03 and
2593.69 cm–1, corresponding to the NH+ stretching vibration in the tertiary amine group
of the drug, disappeared (or shifted) in the resinate. In addition, new absorption bands
emerged around 3022.89 cm–1 in the resinate spectra. In comparison with certain absorp-
tion bands around this wavelength position, the distinct increase in intensity of the new
absorption bands in the resinate spectra indicates that they are not the usual absorption
bands associated with either pure drug or resin. The formation of new chemical bonds
would be expected to result in emergence of additional absorption bands or alterations
in wavenumber position (18). From this standpoint, the above finding can imply that
dextromethorphan in resinate exists in the positively charged form (NH+ group of drug
in resinate), which interacts with the sulfonate group of the resin in the complex. This
kind of ionic association is referred to as a »salt bridge«. Like the hydrogen-bonding ef-
fect, the degree of this ionic association, which closely relates to the H-donating and ac-
cepting ability of an ion pair, significantly affects the NH+ stretching. As the ionic associa-
tion increases, the NH+ stretching decreases and subsequently shifts to a lower frequency,
and vice versa. Therefore, the shifting of the NH+ stretching of the drug to a higher fre-
quency in resinate suggests that the ionic association in resinate is weaker than in the
drug (19).
Evaluation of tablets
Initially, tablets containing superdisintegrants in concentrations of 3, 5, and 10 %
(m/m) were tested for disintegration time. The tablets containing CP showed fast disin-
tegration (8–10 s) followed by SSG (13–17 s) and Amberlite IRP88 (13–20 s) (Table III).
Based on the results, CP at a concentration of 10 % was selected for the formulations of
ODTs.
Tablet thickness and hardness were maintained at 4.5 ± 0.1 mm and 3.5 ± 0.5 kg cm–2,
respectively, for all formulations. The mass variation (less than 7.5 %), friability (less than
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Fig. 5. FTIR spectra of dextrome-
thorphan, Amberlite IRP69, phy-
sical mixture and drug resinate.
1 %) and content uniformity of tablets (95–100 %) of all batches (A1, A2 and A3) were
found to be within the limits. Wetting time of A1 formulation of 19.2 ± 0.4 s was lower
compared to A2 and A3 formulations (65.3 ± 0.6 and 35.6 ± 0.8 s, respectively) (Table IV).
Faster wetting of A1 tablets containing Avicel PH 101 might be due to its rapid water ab-
sorbing nature involving both capillary and swelling mechanisms (20). Water absorption
ratio, R, of formulations containing Pearlitol® SD 200 (132.5 ± 1.8) was higher than that
of Avicel PH 101 and combination of Pearlitol® SD 200 and Avicel PH 101 (82.7 ± 1.6 and
116.7 ± 1.3, respectively) (Table IV). Formulation containing a higher amount of Pearli-
tol® SD 200 showed increased wetting and disintegration time. Increase in wetting and
disintegration time may be due to the increase in polyol quantity in the tablet formula-
tion. As polyols are readily soluble in water, there is a competition between spray-dried
mannitol and CP for water penetrating into the tablet, consequently leading to poor
swelling of CP with subsequent delay in disintegration. These results are consistent with
the reports of Shagufta et al. (21).
Taste evaluation and in vivo disintegration time
Taste evaluation was performed on six healthy human volunteers and the results
are given in Table V. Pure drug was felt bitter immediately after it was kept on the ton-
gue and the sense persisted up to 10 minutes. However, drug bitterness was masked af-
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Table IV. Evaluation parameters of DXM oral disintegrating tablets
Parameter A1 A2 A3
WT (s) 19.2 ± 0.4 65.3 ± 0.7 35.6 ± 0.8
Water absorption ratio 82.69 ± 1.6 132.5 ± 1.8 116.7 ± 1.7
In vitro DT (s) 5.89 ± 1.2 19.2 ± 2.4 9.27 ± 1.9
Oral DT (s) 26.7 ± 1.6 45.39 ± 2.7 32.56 ± 1.7
WT and DT represent wetting time and disintegration time, respectively.
Table V. Comparative taste evaluation
Form of DXM
Degree of bitterness after time
10 s 1 min 5 min 10 min
Pure drug 3 3 3 3
Drug resinate 0 0 0.5 0
Unflavoured tablet
with drug resinate
0 0 0 0
Flavoured tablet
with drug resinate
0+ 0+ 0+ 0+
Results are the mean of 6 observations. + indicates palatability.
ter its binding to the resin. Among the formulations tested, unflavoured tablets exhibi-
ted no bitterness even after 10 min whereas flavoured tablets exhibited palatability. Since
the drug is not in the native form and is bound to the resin, reduced availability of free
drug in the saliva could have led to the masking of the bitter taste.
As regards wetting time, R value, in vitro DT, and cumulative drug released, formu-
lations containing CP with Avicel pH 101 were considered to be better than those con-
taining CP with Pearlitol® SD 200. A1 formulations showed lower DT with 5.9 ± 1.2 s
compared to A2 and A3 (19.2 ± 2.4 and 9.3 ± 1.9, respectively). Complete in vivo disinte-
gration was achieved within 26.7 ± 1.6 s for A1 formulation whereas it increased to 45.4 ±
2.7 and 32.6 ± 1.7 for A2 and A3 formulations (Table IV). Based on in vitro and in vivo dis-
integration, A1 was considered to be the optimal ODT formulation among all the formu-
lations tested.
In vitro release
Based on the investigation, tablets of batch A1 were considered to possess the best
physical properties accompanied with fast disintegration time. Therefore, to understand
the dissolution behavior, the in vitro release study was conducted for optimized DXM
oral disintegrating tablets (A1) and compared with the conventional, directly com-
pressed DXM tablet that contains pure drug in place of drug-resin complex. Since ODT
is meant to release the drug in stomach and the drug release from resinate is dependent
on the exchange of hydrogen ions, the dissolution was conducted in simulated gastric
fluid. The drug release from both formulations was almost 80 % within 60 min (Fig. 6).
However, in case of A1 formulation, the drug release was 55 % in 10 min, which is
higher compared to the drug release from the conventional tablet (40 %). The dissolution
efficiency calculated was 70.9 and 63.8 % for optimized and conventional directly com-
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Fig. 6. In vitro release profiles of opti-
mized formulation (A1) and conventio-
nal tablet (mean ± SD, n = 6).
pressed formulations, respectively. The optimized ODT dissolution behavior was almost
comparable to the conventional tablet, which clearly demonstrates that drug is displaced
from resinate without any delay in the dissolution process despite the fact that the drug
is in complex with ion-exchange resin. Obviously, this could be due to free dissociation
of the drug from resinate due to the exchange with hydrogen ions present in the dissolu-
tion medium. However, longer time was necessary for the drug to dissociate completely
from the resinate.
CONCLUSIONS
The study has revealed the effect of particle size of resin on drug loading and re-
lease. The extent of drug loading and release were higher with small particle size resins
compared to larger particle size resins. Characterization of the ODTs confirmed that ade-
quate taste masking and faster disintegration could be achieved for the optimized (A1)
formulation. Based on the results, it can be concluded that the bitterness of DXM can be
masked with the resin and can be incorporated in ODTs with good dissolution behavior.
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S A @ E T A K
Dizajniranje i evaluacija oralnih raspadaju}ih tableta dekstrometorfan
hidrobromida s maskiranim okusom
MADHUSUDHAN MALLADI, RAJU JUKANTI, RASHMI NAIR, SANJAY WAGH,
HARI SHANKER PADAKANTI i ASHOK MATETI
Cilj rada bio je pripraviti raspadaju}e tablete dekstrometorfan hidrobromida (DXM)
za oralnu primjenu (ODT) prihvatljivog okusa s namjerom da se pomogne pacijentima
svih dobnih skupina. Gorki okus ljekovite tvari maskiran je vezanjem lijeka na ionsko-
-izmjenjiva~ku smolu. Prou~avan je utjecaj veli~ine ~estica smole na koli~inu ljekovite
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tvari koja se mo`e na nju vezati, vrijeme raspadanja in vitro i in vivo, te osloba|anje lijeka
in vitro. Koli~ina vezanog lijeka zna~ajno se pove}ava sa smanjenjem veli~ine ~estica
smole. DSC i XRPD studije pokazuju da prilikom vezanja kristalini~ni oblik lijeka prela-
zi u amorfni. Osloba|anje ljekovite tvari izra~unato za optimizirane ODT i izravno kom-
primirane tablete vrlo je sli~no, {to ukazuje na slobodno osloba|anje lijeka iz smole.
Gorki okus DXM mo`e se maskirati vezanjem ljekovite tvari na ionsko-izmjenjiva~ku
smolu iz koje se mogu pripraviti raspadaju}e tablete za oralnu primjenu.
Klju~ne rije~i: dekstrometorfan hidrobromid, ionsko-izmjenjiva~ka smola, maskiranje okusa,
sredstvo za raspadanje
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